Deepika Jalota - 18 Jan 2024 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
Chief Development Officer
Signature
/s/ Robert Ticktin, by power of attorney
Issuer symbol
PMVP
Transactions as of
18 Jan 2024
Net transactions value
$0
Form type
4
Filing time
22 Jan 2024, 16:06:16 UTC
Previous filing
18 Sep 2023
Next filing
03 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMVP Common Stock Award $0 +95,555 +319% $0.000000 125,501 18 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMVP Employee Stock Option (right to buy) Award $0 +225,095 $0.000000 225,095 18 Jan 2024 Common Stock 225,095 $1.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 30, 2025.
F2 Shares subject to the option vest in 48 equal monthly installments beginning on February 18, 2024.

Remarks:

Exhibit 24 - Power of Attorney